PR 022

Drug Profile

PR 022

Alternative Names: Hypochlorous acid; PR-022

Latest Information Update: 02 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Puricore
  • Developer Realm Therapeutics
  • Class Chlorine compounds; Noncarboxylic acids; Oxides; Reactive oxygen species; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Atopic dermatitis

Most Recent Events

  • 28 Feb 2017 Realm Therapeutics plans a phase II trial for Atopic dermatitis in USA
  • 28 Feb 2017 US FDA approves IND application for PR 022 in Atopic dermatitis
  • 21 Jun 2016 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top